OCT 25, 2016 12:34 PM PDT

New Compound in Onions Halts Ovarian Cancer Proliferation

WRITTEN BY: Xuan Pham
A study from the University of Japan finds that certain compounds in onions have anticancer effects against ovarian cancer. Onion lovers rejoice!
 
Known for its polarizing taste and pungent smell, onions are high in many vitamins and antioxidants. Studies have linked onions to health benefits, like strengthening the immune system, lowering blood pressure, and even fighting cancer.
 

One compound, aptly called onionin A (ONA), was recently identified by researchers at the Kumamoto University in Japan. ONA is high in sulfur and researchers believed it can squelch a tumor microenvironment. In particular, the team was especially interested in how ONA may act on epithelia ovarian cancer (EOC), which is often associated with tumor-associated macrophages.
 
In pre-clinical trials, the researchers treated EOC cells with the onion-derived compound. They found that ONA directly suppressed cancer cell proliferation. Furthermore, the effect appeared synergistic when combined with other anticancer drugs.
 
When the compound was used to treat a mouse model of EOC, the team found increased survival time. Molecular research also revealed that the signals for chemo-resistance was abolished with the application of ONA, suggesting a mechanism for how ONA acts on cancer cells.
 
The team concluded that “ONA is considered useful for the additional treatment of patients with ovarian cancer owing to its suppression of the pro-tumor activation of [tumor-associated macrophages] and direct cytotoxicity against cancer cells."
 

Of note, this first study to investigate the effect of an onion compound in ovarian cancer did not find any side effects in the animals. This, combined with the promising positive anticancer effects, could mean a faster path to human clinical trials and treatment.
 
Ovarian cancers have one of the highest mortality rates, ranking fifth in cancer deaths among women. Of the 22,000 new estimated cases of ovarian cancer this year, only 10-15 percent of patients will be successfully treated. Unfortunately, in the large percent of remaining patients, the cancer doesn’t respond to treatment, or will inevitably return with a vengeance. As such, research into low risk, natural compounds like ONA may be fruitful to fight this deadly disease.

Additional sources: MNT
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
SEP 10, 2020
Cancer
Pancreatic cancer patients see hope in this newly developed drug
SEP 10, 2020
Pancreatic cancer patients see hope in this newly developed drug
A new drug developed by researchers at the University of Sheffield hopes to improve life expectancy and quality of life ...
OCT 11, 2020
Cancer
Targeting neoantigens to improve immunotherapies
OCT 11, 2020
Targeting neoantigens to improve immunotherapies
Neoantigens are extremely small biomarkers forming from cancer mutations that demonstrate the presence of cancerous cell ...
OCT 25, 2020
Cell & Molecular Biology
Revealing More About the Genetics of Ewing Sarcoma
OCT 25, 2020
Revealing More About the Genetics of Ewing Sarcoma
Ewing sarcoma is a rare kind of cancer that tends to impact young people and occurs in bones or the tissue around them. ...
OCT 29, 2020
Cancer
Eat until you are only 70% full to reduce risk of fatty liver and liver cancer
OCT 29, 2020
Eat until you are only 70% full to reduce risk of fatty liver and liver cancer
Non-alcoholic fatty liver disease is known to be a risk factor for liver cancer because of an excess of fat accumulation ...
NOV 02, 2020
Immunology
New Cancer Drug Reboots Stalled Immunotherapies
NOV 02, 2020
New Cancer Drug Reboots Stalled Immunotherapies
In contrast to traditional chemotherapies, immunotherapies reprogram the patient’s own immune system to fight tumo ...
NOV 02, 2020
Cancer
Age impacts response to melanoma treatment
NOV 02, 2020
Age impacts response to melanoma treatment
Research from the Johns Hopkins Kimmel Cancer Center and Johns Hopkins Bloomberg School of Public Health& ...
Loading Comments...